Company: BLRX
Filing Date: 2025-01-07
Form Type: 424B5
Source: 0001178913-25-000045
Chunk: 13

Company: BioLineRx Ltd.
Filing Date: 2025-01-07
Form: 424B5
Chunk 13
---
 and have no further value. Moreover, following this offering, the market value of the warrants and pre-funded warrants, if any, is uncertain and there can be no assurance that the market value of warrants or and pre-funded warrants will equal or exceed their imputed offering price. There can be no assurance that the market price of the ADSs will ever equal or exceed the exercise price of the warrants and pre-funded warrants, and consequently, whether it will ever be profitable for holders of the warrants to exercise their respective warrants. Holders of our warrants and pre-funded warrants will have no rights as ADS holders until such holders exercise their respective warrants and pre-funded warrants and acquire our ADSs. Until holders of the warrants and pre-funded warrants acquire our ADSs upon exercise of their respective warrants, such holders will have no rights with respect to the ADSs underlying such warrants. Upon exercise of the warrants and pre-funded warrants, the holders thereof will be entitled to exercise the rights of a holder of ADSs only as to matters for which the record date occurs after the exercise date. S - 6 We may not receive any additional funds upon the exercise of the warrants and pre-funded warrants being offered. The pre-funded warrants, and in certain limited circumstances, the warrants, may be exercised by way of a cashless exercise, meaning that the holder may not pay a cash purchase price upon exercise, but instead would receive upon such exercise the net number of ADSs determined according to the formula set forth in the warrant. Accordingly, we may not receive any additional funds upon the cashless exercise of the pre-funded warrants and warrants or if the pre-funded warrants and warrants altogether are not exercised at all. Our ADSs and ordinary shares are listed on two markets, and this may result in price variations that could affect the trading price of our ADSs and ordinary shares. Our ADSs are listed on Nasdaq, and our ordinary shares are listed on the TASE, both under the symbol “BLRX.” Trading in our securities on these markets is made in different currencies (U.S. Dollars on Nasdaq and NIS on the TASE), and at different times (due to the different time zones, different trading days and different public holidays in the United States and Israel). The relative trading prices of our securities on these two markets may differ due to these and other factors. Any decrease in the trading price of our securities on one exchange could cause a decrease in the trading price of our securities on the other exchange. We conduct a substantial part of our operations in Israel and therefore